Fiasp and the ONSET5 Trial – What Novo Nordisk found in the CSII (pump) Clinical trial
Is Hba1C a poor yardstick for determining access to new T1D treatments in the real world
Enough is enough. I can’t go on…. Details of the EMA Submission Fiasp CSII study
Fiasp – going off-label. Attempting to handle the unwanted side effects and retain the rapid effectiveness
Defining an “Artificial Pancreas”. Where are we with DIY systems? #WeAreNotWaiting